Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
Gilead Sciences' hepatitis C drug Sovaldi may be worth the sticker price. But it's too expensive for the U.K.'s health system to bear. That's the assessment in some National Health Service documents obtained by the Health Service Journal.
Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.
On "60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.
Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.
Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand--and adding an enormous premium along the way. Once again, the cost increase promises to be huge, The Street reports: Analysts figure on a list price of $60,000 to $80,000 per year.
One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based group of more than 130 hospitals, is barring Genentech sales reps at the door.
Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim the new regime--which restricts Avastin, Rituxan and Herceptin to a half-dozen specialty distributors--will cost them big money.
Pharma's social media evangelists have been urging companies to lend an ear to the chatter on Twitter, Facebook, patient forums, physician networking sites and the like. It's a way to engage with patients, monitor doctors' opinions, tailor marketing and spot safety concerns, they say.
Hospira's FDA woes have moved to Australia. The agency scolded the U.S.-based company in a warning letter based on an injectables plant inspection in late February and early March, according to a Wednesday securities filing.
A few things are certain about the Sunshine Act data that hit the Internet Tuesday afternoon. One, it's incomplete. Two, it's controversial. Three, the numbers are pretty staggering, with $3.5 billion in payments to 546,000 doctors and 1,360 research institutions over a 5-month period.